{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:07:18Z","timestamp":1789542438669,"version":"build-2803163510"},"reference-count":124,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1017584"],"award-info":[{"award-number":["OPP1017584"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI081803"],"award-info":[{"award-number":["AI081803"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Filarial worms cause multiple debilitating diseases in millions of people worldwide, including river blindness. Currently available drugs reduce transmission by killing larvae (microfilariae), but there are no effective cures targeting the adult parasites (macrofilaricides) which survive and reproduce in the host for very long periods. To identify effective macrofilaricides, we carried out phenotypic screening of a library of 2121 approved drugs for clinical use against adult Brugia pahangi and prioritized the hits for further studies by integrating those results with a computational prioritization of drugs and associated targets. This resulted in the identification of 18 hits with anti-macrofilaricidal activity, of which two classes, azoles and aspartic protease inhibitors, were further expanded upon. Follow up screening against Onchocerca spp. (adult Onchocerca ochengi and pre-adult O. volvulus) confirmed activity for 13 drugs (the majority having IC50 &lt; 10 \u03bcM), and a counter screen of a subset against L. loa microfilariae showed the potential to identify selective drugs that prevent adverse events when co-infected individuals are treated. Stage specific activity was also observed. Many of these drugs are amenable to structural optimization, and also have known canonical targets, making them promising candidates for further optimization that can lead to identifying and characterizing novel anti-macrofilarial drugs.<\/jats:p>","DOI":"10.3390\/pathogens10010071","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T01:33:29Z","timestamp":1610674409000},"page":"71","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-8972","authenticated-orcid":false,"given":"Rahul","family":"Tyagi","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, 4523 Clayton Ave., St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina A.","family":"Bulman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidelis","family":"Cho-Ngwa","sequence":"additional","affiliation":[{"name":"ANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, Buea CM-00237, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Marcellino","sequence":"additional","affiliation":[{"name":"Division of Neurocritical Care and Hospital Neurology, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Arkin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"McKerrow","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-3407","authenticated-orcid":false,"given":"Case W.","family":"McNamara","sequence":"additional","affiliation":[{"name":"Calibr, a Division of The Scripps Research Institute, 11119 Torrey Pines Road, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-2128","authenticated-orcid":false,"given":"Matthew","family":"Mahoney","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Tricoche","sequence":"additional","affiliation":[{"name":"Lindsley F. Kimball Research Institute, New York City, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Jawahar","sequence":"additional","affiliation":[{"name":"Lindsley F. Kimball Research Institute, New York City, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Janetka","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-6113","authenticated-orcid":false,"given":"Sara","family":"Lustigman","sequence":"additional","affiliation":[{"name":"Lindsley F. Kimball Research Institute, New York City, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Sakanari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of California San Francisco, 1700 4th Street, San Francisco, CA 94158, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9572-3436","authenticated-orcid":false,"given":"Makedonka","family":"Mitreva","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, 4523 Clayton Ave., St. Louis, MO 63110, USA"},{"name":"McDonnell Genome Institute, Washington University School of Medicine, 4444 Forest Park Ave., St. Louis, MO 63108, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","article-title":"Lymphatic filariasis and onchocerciasis","volume":"376","author":"Taylor","year":"2010","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1469-0691.2011.03586.x","article-title":"Filariasis in Africa-treatment challenges and prospects","volume":"17","author":"Hoerauf","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lustigman, S., Prichard, R.K., Gazzinelli, A., Grant, W.N., Boatin, B.A., McCarthy, J.S., and Basanez, M.G. (2012). A research agenda for helminth diseases of humans: The problem of helminthiases. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001582"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Prichard, R.K., Basanez, M.G., Boatin, B.A., McCarthy, J.S., Garcia, H.H., Yang, G.J., Sripa, B., and Lustigman, S. (2012). A research agenda for helminth diseases of humans: Intervention for control and elimination. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001549"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"King","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Weil, G.J., Bogus, J., Christian, M., Dubray, C., Djuardi, Y., Fischer, P.U., Goss, C.W., Hardy, M., Jambulingam, P., and King, C.L. (2019). The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002839"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: A modelling study","volume":"17","author":"Irvine","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: An oral treatment for human onchocerciasis","volume":"18","author":"Milton","year":"2020","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.pt.2003.09.004","article-title":"Mass drug treatment for lymphatic filariasis and onchocerciasis","volume":"19","author":"Molyneux","year":"2003","journal-title":"Trends Parasitol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00001432-200104000-00008","article-title":"Current status and future prospects of the Global Lymphatic Filariasis Programme","volume":"14","author":"Molyneux","year":"2001","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1756-3305-7-363","article-title":"Multidimensional complexities of filariasis control in an era of large-scale mass drug administration programmes: A can of worms","volume":"7","author":"Molyneux","year":"2014","journal-title":"Parasites Vectors"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0001-706X(91)90015-C","article-title":"The reproductive lifespan of Onchocerca volvulus in West African savanna","volume":"48","author":"Plaisier","year":"1991","journal-title":"Acta Trop."},{"key":"ref_13","unstructured":"WHO (2010). Global programme to eliminate lymphatic filariasis. Wkly Epidemiol. Rec., 85, 365\u2013372."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ottesen, E.A., Hooper, P.J., Bradley, M., and Biswas, G. (2008). The global programme to eliminate lymphatic filariasis: Health impact after 8 years. PLoS Negl. Trop. Dis., 2.","DOI":"10.1371\/journal.pntd.0000317"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chu, B.K., Hooper, P.J., Bradley, M.H., McFarland, D.A., and Ottesen, E.A. (2010). The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000\u20132007). PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000708"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Diawara, L., Traore, M.O., Badji, A., Bissan, Y., Doumbia, K., Goita, S.F., Konate, L., Mounkoro, K., Sarr, M.D., and Seck, A.F. (2009). Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: First evidence from studies in Mali and Senegal. PLoS Negl. Trop. Dis., 3.","DOI":"10.1371\/journal.pntd.0000497"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Traore, M.O., Sarr, M.D., Badji, A., Bissan, Y., Diawara, L., Doumbia, K., Goita, S.F., Konate, L., Mounkoro, K., and Seck, A.F. (2012). Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: Final results of a study in Mali and Senegal. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001825"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"NTD Modelling Consortium Onchocerciasis Group (2019). The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group. Gates Open Res., 3, 1545.","DOI":"10.12688\/gatesopenres.13067.1"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"NTD Modelling Consortium Lymphatic Filariasis Group (2019). The roadmap towards elimination of lymphatic filariasis by 2030: Insights from quantitative and mathematical modelling. Gates Open Res., 3, 1538.","DOI":"10.12688\/gatesopenres.13065.1"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Turner, H.C., Churcher, T.S., Walker, M., Osei-Atweneboana, M.Y., Prichard, R.K., and Basanez, M.G. (2013). Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002169"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/ciu467","article-title":"Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa","volume":"59","author":"Turner","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_22","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1545\u20131602."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1093\/inthealth\/ihv077","article-title":"Neglected tropical diseases in Africa: A new paradigm","volume":"8","author":"Hopkins","year":"2016","journal-title":"Int. Health"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kim, Y.E., Remme, J.H., Steinmann, P., Stolk, W.A., Roungou, J.B., and Tediosi, F. (2015). Control, elimination, and eradication of river blindness: Scenarios, timelines, and ivermectin treatment needs in Africa. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003777"},{"key":"ref_25","unstructured":"African Programme for Onchocerciasis Control (APOC) (2014). Report of the Thirty-Eight Session of the Technical Consultative Committee: Ouagadougou, WHO. Document Number: DIR\/COORD\/APOC\/REP\/TCC38."},{"key":"ref_26","unstructured":"The U.S. Food and Drug Administration (FDA), and The United States Department of Agriculture (USDA) (2018). Drug Approval Package: Moxidectin."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Awadzi, K., Opoku, N.O., Attah, S.K., Lazdins-Helds, J., and Kuesel, A.C. (2014). A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002953"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: A randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13071-015-0779-4","article-title":"The potential impact of moxidectin on onchocerciasis elimination in Africa: An economic evaluation based on the Phase II clinical trial data","volume":"8","author":"Turner","year":"2015","journal-title":"Parasites Vectors"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1756-3305-7-307","article-title":"Innovative tools for assessing risks for severe adverse events in areas of overlapping Loa loa and other filarial distributions: The application of micro-stratification mapping","volume":"7","author":"Cano","year":"2014","journal-title":"Parasites Vectors"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2883-2-S1-S4","article-title":"Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon","volume":"2","author":"Boussinesq","year":"2003","journal-title":"Filaria J."},{"key":"ref_32","first-page":"286re284","article-title":"Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope","volume":"7","author":"Bakalar","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Boatin, B.A., Basanez, M.G., Prichard, R.K., Awadzi, K., Barakat, R.M., Garcia, H.H., Gazzinelli, A., Grant, W.N., McCarthy, J.S., and N\u2019Goran, E.K. (2012). A research agenda for helminth diseases of humans: Towards control and elimination. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001547"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Osei-Atweneboana, M.Y., Awadzi, K., Attah, S.K., Boakye, D.A., Gyapong, J.O., and Prichard, R.K. (2011). Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0000998"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Doyle, S.R., Bourguinat, C., Nana-Djeunga, H.C., Kengne-Ouafo, J.A., Pion, S.D.S., Bopda, J., Kamgno, J., Wanji, S., Che, H., and Kuesel, A.C. (2017). Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005816"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lustigman, S., and McCarter, J.P. (2007). Ivermectin Resistance in Onchocerca volvulus: Toward a Genetic Basis. PLoS Negl. Trop. Dis., 1.","DOI":"10.1371\/journal.pntd.0000076"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/cid\/civ363","article-title":"Doxycycline Leads to Sterility and Enhanced Killing of Female Onchocerca volvulus Worms in an Area with Persistent Microfilaridermia After Repeated Ivermectin Treatment: A Randomized, Placebo-Controlled, Double-Blind Trial","volume":"61","author":"Debrah","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cmdc.201800755","article-title":"Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease","volume":"14","author":"Veale","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Voronin, D., Tricoche, N., Jawahar, S., Shlossman, M., Bulman, C.A., Fischer, C., Suderman, M.T., Sakanari, J.A., and Lustigman, S. (2019). Development of a preliminary in vitro drug screening assay based on a newly established culturing system for pre-adult fifth-stage Onchocerca volvulus worms. PLoS Negl. Trop. Dis., 13.","DOI":"10.1371\/journal.pntd.0007108"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"International Helminth Genomes Consortium (2019). Comparative genomics of the major parasitic worms. Nat. Genet., 51, 163\u2013174.","DOI":"10.1038\/s41588-018-0262-1"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Marcellino, C., Gut, J., Lim, K.C., Singh, R., McKerrow, J., and Sakanari, J. (2012). WormAssay: A novel computer application for whole-plate motion-based screening of macroscopic parasites. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001494"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: Towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/ijms15022024","article-title":"Adenosine receptors: Expression, function and regulation","volume":"15","author":"Sheth","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid receptors","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.cellbio.22.010605.093503","article-title":"Modification of proteins by ubiquitin and ubiquitin-like proteins","volume":"22","author":"Kerscher","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/ijc.29519","article-title":"HIF-1 at the crossroads of hypoxia, inflammation, and cancer","volume":"138","author":"Balamurugan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.redox.2015.08.006","article-title":"The role of lipoxygenases in pathophysiology; new insights and future perspectives","volume":"6","author":"Mashima","year":"2015","journal-title":"Redox Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2165\/00003495-200767090-00005","article-title":"Dihydropyridine calcium channel antagonists in the management of hypertension","volume":"67","author":"Epstein","year":"2007","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsps.2012.03.002","article-title":"Quinoline: A versatile heterocyclic","volume":"21","author":"Marella","year":"2013","journal-title":"Saudi Pharm. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0378-8741(00)00251-8","article-title":"Studies on the vascular effects of the fractions and phenolic compounds isolated from Viscum album ssp. album","volume":"72","author":"Deliorman","year":"2000","journal-title":"J. Ethnopharmacol."},{"key":"ref_54","first-page":"339","article-title":"Calcium-antagonists and islet function X. Effect of suloctidie","volume":"228","author":"Malaisse","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1016\/0006-2952(79)90419-2","article-title":"Effect of suloctidil on Na+\/K+ ATPase activity and on membrane fluidity in rat brain synaptosomes","volume":"28","author":"Chatelain","year":"1979","journal-title":"Biochem. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/nar\/30.1.412","article-title":"TTD: Therapeutic Target Database","volume":"30","author":"Chen","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1021\/jm50001a013","article-title":"1-[3-(Diarylamino)propyl]piperidines and related compounds, potential antipsychotic agents with low cataleptogenic profiles","volume":"28","author":"Wise","year":"1985","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12012-015-9322-2","article-title":"Why Can dl-Sotalol Prolong the QT Interval In Vivo Despite Its Weak Inhibitory Effect on hERG K(+) Channels In Vitro? Electrophysiological and Pharmacokinetic Analysis with the Halothane-Anesthetized Guinea Pig Model","volume":"16","author":"Katagi","year":"2016","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neulet.2011.11.026","article-title":"Inhibition of sensory neuronal TRPs contributes to anti-nociception by butamben","volume":"506","author":"Bang","year":"2012","journal-title":"Neurosci. Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jps.3030490107","article-title":"Some aspects of the pharmacology of clemizole hydrochloride","volume":"49","author":"Finkelstein","year":"1960","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/mol.114.093229","article-title":"Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5","volume":"86","author":"Richter","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"ref_62","first-page":"32","article-title":"Individual Approach to the Use of Medications to Normalize Situational Anxiety under the Psycho-Emotional Stress","volume":"49","author":"Ivanov","year":"2015","journal-title":"Aviakosm. Ekolog. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.bmc.2014.12.030","article-title":"Saccharin: A lead compound for structure-based drug design of carbonic anhydrase IX inhibitors","volume":"23","author":"Mahon","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/jm970636+","article-title":"Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy","volume":"41","author":"Kempf","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/0008-5472.CAN-03-2677","article-title":"HIV-1 protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo","volume":"64","author":"Ikezoe","year":"2004","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"Gunthard","year":"2014","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"15810","DOI":"10.1073\/pnas.1106030108","article-title":"Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET","volume":"108","author":"Schlessinger","year":"2011","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13321-016-0142-6","article-title":"Literature information in PubChem: Associations between PubChem records and scientific articles","volume":"8","author":"Kim","year":"2016","journal-title":"J. Cheminform."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.00790-10","article-title":"Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis","volume":"54","author":"Carvalho","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/mol.62.6.1364","article-title":"Discovery of novel targets of quinoline drugs in the human purine binding proteome","volume":"62","author":"Graves","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12936-018-2248-y","article-title":"Primaquine-induced haemolysis in females heterozygous for G6PD deficiency","volume":"17","author":"Chu","year":"2018","journal-title":"Malar. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.2042-7158.1967.tb09604.x","article-title":"Evidence for dopamine receptor stimulation by apomorphine","volume":"19","author":"Anden","year":"1967","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00426104","article-title":"Adrenergic receptor blocking agents: Effects on central noradrenaline and dopamine receptors and on motor activity","volume":"38","author":"Anden","year":"1974","journal-title":"Psychopharmacologia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/AAC.02067-12","article-title":"Azole affinity of sterol 14alpha-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens","volume":"57","author":"Warrilow","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1038\/s41598-017-07495-z","article-title":"Characterisation of sterol biosynthesis and validation of 14alpha-demethylase as a drug target in Acanthamoeba","volume":"7","author":"Thomson","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/eri.13.17","article-title":"Sertaconazole: An antifungal agent for the topical treatment of superficial candidiasis","volume":"11","author":"Giusiano","year":"2013","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1128\/AEM.01195-14","article-title":"Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasitica through inhibition of sterol 14alpha-demethylase (CYP51)","volume":"80","author":"Warrilow","year":"2014","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1021\/acs.jmedchem.5b01718","article-title":"Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic","volume":"59","author":"Pace","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.pt.2016.08.013","article-title":"25 Years of the Onchocerca ochengi Model","volume":"32","author":"Makepeace","year":"2016","journal-title":"Trends Parasitol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"Gardon","year":"1997","journal-title":"Lancet"},{"key":"ref_82","unstructured":"Drugs for Neglected Diseases Initiative (2020, November 11). Filaria: River blindness, Oxfendazole. Available online: https:\/\/dndi.org\/research-development\/portfolio\/oxfendazole\/."},{"key":"ref_83","unstructured":"Drugs for Neglected Diseases Initiative (2020, November 11). Filaria: River Blindness, Emodepside. Available online: https:\/\/dndi.org\/research-development\/portfolio\/emodepside\/."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hubner, M.P., Martin, C., Specht, S., Koschel, M., Dubben, B., Frohberger, S.J., Ehrens, A., Fendler, M., Struever, D., and Mitre, E. (2020). Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008427"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kashyap, S.S., Verma, S., Voronin, D., Lustigman, S., Kulke, D., Robertson, A.P., and Martin, R.J. (2019). Emodepside has sex-dependent immobilizing effects on adult Brugia malayi due to a differentially spliced binding pocket in the RCK1 region of the SLO-1 K channel. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1008041"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the development of azole derivatives","volume":"10","author":"Maertens","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9085","DOI":"10.1038\/s41598-019-45548-7","article-title":"Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics","volume":"9","author":"Tyagi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1021\/jm030191r","article-title":"Identification and prediction of promiscuous aggregating inhibitors among known drugs","volume":"46","author":"Seidler","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1021\/jm070336k","article-title":"Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors","volume":"50","author":"Choi","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/mol.113.085902","article-title":"Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1","volume":"84","author":"Mast","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1810137115","article-title":"The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis","volume":"115","author":"Janes","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138161207779313560","article-title":"Aspartic proteases in drug discovery","volume":"13","author":"Eder","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ardp.200700267","article-title":"Design of potent aspartic protease inhibitors to treat various diseases","volume":"341","author":"Nguyen","year":"2008","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"ref_96","unstructured":"WHO (2019). The Selection and Use of Essential Medicines: Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (Including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children), WHO."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-308X(08)60243-2","article-title":"Proteinases and associated genes of parasitic helminths","volume":"43","author":"Tort","year":"1999","journal-title":"Adv. Parasitol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Xu, J., Liu, R.D., Bai, S.J., Hao, H.N., Yue, W.W., Xu, Y.X.Y., Long, S.R., Cui, J., and Wang, Z.Q. (2020). Molecular characterization of a Trichinella spiralis aspartic protease and its facilitation role in larval invasion of host intestinal epithelial cells. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008269"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vetpar.2012.06.029","article-title":"Molecular characterization of 45 kDa aspartic protease of Trichinella spiralis","volume":"190","author":"Park","year":"2012","journal-title":"Vet. Parasitol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/367708","article-title":"Hookworm aspartic protease, Na-APR-2, cleaves human hemoglobin and serum proteins in a host-specific fashion","volume":"187","author":"Williamson","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.exppara.2004.06.006","article-title":"Onchocerca volvulus: Expression and immunolocalization of a nematode cathepsin D-like lysosomal aspartic protease","volume":"107","author":"Jolodar","year":"2004","journal-title":"Exp. Parasitol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/bip.22780","article-title":"New directions for protease inhibitors directed drug discovery","volume":"106","author":"Hamada","year":"2016","journal-title":"Biopolymers"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2174\/1389203717666160809155749","article-title":"Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections","volume":"18","author":"Monika","year":"2017","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Castilho, V.V.S., Goncalves, K.C.S., Rebello, K.M., Baptista, L.P.R., Sangenito, L.S., Santos, H.L.C., Branquinha, M.H., Santos, A.L.S., Menna-Barreto, R.F.S., and Guimaraes, A.C. (2018). Docking simulation between HIV peptidase inhibitors and Trypanosoma cruzi aspartyl peptidase. BMC Res. Notes, 11.","DOI":"10.1186\/s13104-018-3927-z"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"D343","DOI":"10.1093\/nar\/gkv1118","article-title":"Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors","volume":"44","author":"Rawlings","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","article-title":"Cathepsin D-many functions of one aspartic protease","volume":"68","author":"Benes","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0003-9861(88)90106-3","article-title":"Proteases of the nematode Caenorhabditis elegans","volume":"261","author":"Sarkis","year":"1988","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_109","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS (Auckl.)"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"16216","DOI":"10.1038\/nmicrobiol.2016.216","article-title":"The genome of Onchocerca volvulus, agent of river blindness","volume":"2","author":"Cotton","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/sj.bjp.0704823","article-title":"Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative","volume":"136","author":"Rigobello","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s13071-017-2515-8","article-title":"Successful long-term maintenance of Mansonella perstans in an in vitro culture system","volume":"10","author":"Njouendou","year":"2017","journal-title":"Parasites Vectors"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"561","DOI":"10.14411\/fp.2014.068","article-title":"Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models","volume":"61","author":"Verma","year":"2014","journal-title":"Folia Parasitol. (Praha)"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1073\/pnas.1619820114","article-title":"Functional genomics in Brugia malayi reveal diverse muscle nAChRs and differences between cholinergic anthelmintics","volume":"114","author":"Verma","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3762\/bjoc.16.105","article-title":"Anthelmintic drug discovery: Target identification, screening methods and the role of open science","volume":"16","author":"Partridge","year":"2020","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_116","unstructured":"Marcellino, C. (2020, September 23). GitHub Repository. Available online: https:\/\/github.com\/chrismarcellino\/wormassay."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Bulman, C.A., Bidlow, C.M., Lustigman, S., Cho-Ngwa, F., Williams, D., Rascon, A.A., Tricoche, N., Samje, M., Bell, A., and Suzuki, B. (2015). Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003534"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"key":"ref_119","first-page":"D762","article-title":"WormBase: A modern Model Organism Information Resource","volume":"48","author":"Harris","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13059-019-1832-y","article-title":"OrthoFinder: Phylogenetic orthology inference for comparative genomics","volume":"20","author":"Emms","year":"2019","journal-title":"Genome Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: Improvements in performance and usability","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","article-title":"Jalview Version 2\u2014A multiple sequence alignment editor and analysis workbench","volume":"25","author":"Waterhouse","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/sysbio\/syq010","article-title":"New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0","volume":"59","author":"Guindon","year":"2010","journal-title":"Syst. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/bioinformatics\/btn307","article-title":"ChemmineR: A compound mining framework for R","volume":"24","author":"Cao","year":"2008","journal-title":"Bioinformatics"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/1\/71\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:11:16Z","timestamp":1760159476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/1\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["pathogens10010071"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10010071","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}